The recent blooming of therapeutic aptamers

被引：0
作者：
Cesarini, Valeriana [1 ]
Appleton, Silvia Lucia [1 ]
de Franciscis, Vittorio [1 ]
Catalucci, Daniele [1 ,2 ]
机构：
[1] Natl Res Council CNR, Inst Genet & Biomed Res IRGB, Milan, Italy
[2] IRCCS Humanitas Res Hosp, Humanitas Cardio Ctr, Milan, Italy
来源：
MOLECULAR ASPECTS OF MEDICINE | 2025年 / 102卷
关键词：
RNA; DNA; Aptamer; Oligonucleotide; ONT drug; Therapeutic; TARGETING 4-1BB COSTIMULATION; DNA APTAMER; RNA; SELECTION; OLIGONUCLEOTIDES; EVOLUTION; DELIVERY; NOX-A12; CXCL12; SELEX;
D O I：
10.1016/j.mam.2025.101350
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
In the dynamic landscape of biomedical research, therapeutic RNA aptamers have recently come to the forefront, showing significant potential in diagnostics and therapeutics. This review aims to raise awareness of aptamer technology within the scientific community by exploring the progress made in the therapeutic field, from the lessons learned in research to the future opportunities and impact that these innovative molecules are increasingly having on society to meet current health needs, i.e. targeted and personalized therapies.
引用
收藏
页数：9
相关论文
共 87 条
  • [1] Alogna A., Berboth L., Faragli A., Otvos J., Lo Muzio F.P., di Mauro V., Modica J., Quarta E., Semmler L., Deissler P.M., Berger Y.W., Tran K.L., de Marchi B., Longinotti-Buitoni G., Degli Esposti L., Guillot E., Bazile D., Iafisco M., Dotti A., Bang M.L., de Luca C., Brandenberger C., Benazzi L., di Silvestre D., de Palma A., Primessnig U., Hohendanner F., Perna S., Buttini F., Colombo P., Muhlfeld C., Steendijk P., Mauri P., Tschope C., Borlaug B., Pieske B.M., Attanasio P., Post H., Heinzel F
  • [2] Appella D.H., Non-natural nucleic acids for synthetic biology, Curr. Opin. Chem. Biol., 13, 5-6, pp. 687-696, (2009)
  • [3] Booth B.J., Nourreddine S., Katrekar D., Savva Y., Bose D., Long T.J., Huss D.J., Mali P., RNA editing: expanding the potential of RNA therapeutics, Mol. Ther., 31, 6, pp. 1533-1549, (2023)
  • [4] Chauhan M., Sonali, Shekhar S., Yadav B., Garg V., Dutt R., Mehata A.K., Goswami P., Koch B., Muthu M.S., Singh R.P., AS1411 aptamer/RGD dual functionalized theranostic chitosan-PLGA nanoparticles for brain cancer treatment and imaging, Biomater. Adv., 160, (2024)
  • [5] Chen T., Mahdadi S., Vidal M., Desbene-Finck S., Non-nucleoside inhibitors of DNMT1 and DNMT3 for targeted cancer therapy, Pharmacol. Res., 207, (2024)
  • [6] Cheng C., Chen Y.H., Lennox K.A., Behlke M.A., Davidson B.L., In vivo SELEX for identification of brain-penetrating aptamers, Mol. Ther. Nucleic Acids, 2, 1, (2013)
  • [7] Chowdhury R., Eslami S., Pham C.V., Rai A., Lin J., Hou Y., Greening D.W., Duan W., Role of aptamer technology in extracellular vesicle biology and therapeutic applications, Nanoscale, 16, 24, pp. 11457-11479, (2024)
  • [8] Dasti A., Cid-Samper F., Bechara E., Tartaglia G.G., RNA-centric approaches to study RNA-protein interactions in vitro and in silico, Methods, 178, pp. 11-18, (2020)
  • [9] Dhar P., Samarasinghe R.M., Shigdar S., Antibodies, nanobodies, or aptamers-which is best for deciphering the proteomes of non-model species?, Int. J. Mol. Sci., 21, 7, (2020)
  • [10] Di Mauro V., Lauta F.C., Modica J., Appleton S.L., De Franciscis V., Catalucci D., Diagnostic and therapeutic aptamers: a promising pathway to improved cardiovascular disease management, JACC Basic Transl. Sci., 9, 2, pp. 260-277, (2024)
123456789